Compare Fiverr International Ltd (FVRR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs Neurocrine Biosciences Inc — how do they compare? Fiverr International Ltd trades at $8.8 (market cap $326.79M), while Neurocrine Biosciences Inc trades at $159 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 51.3× Fiverr International Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals.
| FVRR | NBIX | |
|---|---|---|
Market Cap | $326.79M | $16.76B |
Sector | Industrials | Health |
52-Week High | $26.67 | $185.50 |
52-Week Low | $8.75 | $123.10 |
Enterprise Value | $79.18M | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $9.42, up 2.39% on the day, but remains near its 52-week low amid bearish technical signals. The stock shows weak earnings momentum with Q2 2026 misses and lowered 2026 guidance due to AI disruption compressing demand for freelance services. Valuation ratios appear attractive with P/E of 11.63 and P/S of 0.83, while profitability metrics show modest improvement with net income margin at 7.18% for 2025.
The outlook is cautious with significant headwinds from AI adoption threatening Fiverr's core business model. Near-term risks include declining active buyers and revenue pressure, though current valuations may offer contrarian appeal if the company successfully adapts to AI challenges. Wall Street sentiment is neutral with 76% hold ratings and a $10.70 consensus price target suggesting limited upside.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
